NDA 215868 · Exela Pharma
Midazolam In 0.8% Sodium Chloride
Midazolam · Intravenous
DiscontinuedLast checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jul 20, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,448
153 Phase 3, 96 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- MIDAZOLAM IN 0.8% SODIUM CHLORIDE · MIDAZOLAM 50MG/50ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
- MIDAZOLAM IN 0.8% SODIUM CHLORIDE · MIDAZOLAM 100MG/100ML (1MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Midazolam" as an intervention, any sponsor and status, largest first.
- Pediatric Dose Optimization for Seizures in Emergency Medical ServicesPivotal-lookingCompleted
Stanford UniversityAcademic, hospital or other
NCT05121324 · 6,897 participants · Start Aug 8, 2022 · Primary completion Jul 31, 2026
Drug: Standardized seizure protocol; Conventional seizure protocol · For: Seizures
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 20 sites in all
- Anesthesia and Non-small Cell Lung Cancer RecurrencePivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT06330038 · 5,384 participants (planned) · Start Aug 5, 2024 · Primary completion Dec 31, 2028
Drug: Propofol; Inhaled anesthetics · For: Non-small Cell Lung Cancer; Surgery; Anesthesia
Sites: Seoul, South Korea
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short OperationPivotal-lookingStatus unknown
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT02635802 · 1,500 participants (planned) · Start Dec 2015 · Primary completion Jun 2016
Drug: Remifentanil; Lidocaine and 2 more · For: Critical Illness
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPivotal-lookingRecruiting
ExelixisIndustry
NCT05176483 · 1,394 participants (planned) · Start Dec 14, 2021 · Primary completion Jan 31, 2027
Drug: Zanzalintinib; Nivolumab and 5 more · For: Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC) and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 122 sites in all
- Impact of Anesthesia Maintenance Methods on 5-year Survival After SurgeryPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT05343260 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 30, 2022
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Guiyang, China · 15 sites in all
- Impact of Anesthesia Maintenance Methods on Long-term SurvivalPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT02660411 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 29, 2017
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Shenzhen, China · 17 sites in all
- A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery PatientsPivotal-lookingCompleted
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT02117401 · 1,152 participants · Start Jan 2012 · Primary completion Jun 2013
Drug: mivacurium chloride; midazolam and 3 more · For: Efficacy and Safety of Mivacurium Chloride for Pediatric Patients
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.
Jakob SM, Ruokonen E, Grounds RM, et al. · JAMA 2012 · Comparative Study, Multicenter Study
- A systematic review and meta-analysis of propofol versus midazolam sedation in adult intensive care (ICU) patients.
Garcia R, Salluh JIF, Andrade TR, et al. · J Crit Care 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Remimazolam for procedural sedation: A systematic review with meta-analyses and trial sequential analyses.
Pingel L, Maagaard M, Tvarnø CD, et al. · Eur J Anaesthesiol 2025 · Systematic Review, Meta-Analysis
- Optimizing pediatric premedication for general anesthesia: A comprehensive Bayesian network meta-analysis.
Wegner GRM, Wegner BFM, Cumming HS, et al. · J Clin Anesth 2025 · Network Meta-Analysis, Systematic Review
- Nitrous Oxide and Midazolam Sedation: A Systematic Review and Meta-Analysis.
Sivaramakrishnan G, Sridharan K · Anesth Prog 2017 · Meta-Analysis, Systematic Review
- Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer.
Yasuda S, Sugano K, Matsuda Y, et al. · Jpn J Clin Oncol 2023 · Meta-Analysis, Systematic Review
Sponsor: Exela Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.